This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Endogenous opioid peptides such as α-neoendorphin, Met-enkephalin-Arg-Phe, and endomorphin-1 exhibit distinct biased agonism profiles at the μ-opioid receptor compared to the synthetic agonist DAMGO, indicating natural ligand-specific signaling biases.
Why it matters
Understanding natural biased agonism at the μ-opioid receptor can guide the design of new opioid drugs that target specific signaling pathways, potentially improving pain management and reducing adverse effects.
How the study worked
The study used a common cellular system to measure multiple signaling pathways activated by endogenous opioid peptides and the synthetic agonist DAMGO. Techniques included assays for G protein activation, cAMP inhibition, ERK1/2 phosphorylation, β-arrestin recruitment, and receptor trafficking, combined with a novel analytical method to quantify biased agonism.
What this study cannot tell us
The study was conducted in vitro using a single cellular background, so it remains to be confirmed whether these biased signaling profiles translate to different physiological effects in living organisms.
Read the original research
Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.
Molecular pharmacology, 88(2), 335-46
Citation
Thompson, Georgina L; Lane, J Robert; Coudrat, Thomas; Sexton, Patrick M; Christopoulos, Arthur; Canals, Meritxell. (2015). Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.. Molecular pharmacology, 88(2), 335-46. https://doi.org/10.1124/mol.115.098848